Leo Pharma AS - Company Profile
Powered by 
All the sales intelligence you need on Leo Pharma AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Leo Pharma AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Leo Pharma AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
LEO Pharma AS (LEO Pharma), a subsidiary of LEO Foundation, is a pharmaceutical company. It focuses on medical dermatology and specialized treatments. The company is developing therapies for skin conditions such as psoriasis, eczema, acne, and infections, alongside providing anticoagulant treatments for cancer patients. LEO Pharma’s pipeline includes delgocitinib, tralokinumab, spesolimab calcipotriol and betamethasone dipropionate, temtokibart, IL-1RAcP, STAT65, topical STAT6 delgocitinib for chronic hand eczema, TMB-001 for congenital ichthyosis, and temtokibart for atopic dermatitis. It is also advancing anti-inflammatory candidates in immunology, including LEO 158968 and LP0128. The company operates manufacturing sites and collaborates with contract manufacturers and API suppliers to ensure a reliable product supply for its treatments. LEO Pharma is headquartered in Ballerup, Denmark.
Headquarters
Denmark
Address
Industriparken 55, Ballerup, 2750
Website
www.leo-pharma.com
Telephone
45 44 945888
No of Employees
4,265
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$1.7B
Leo Pharma AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapy Areas: | Adtralza |
| Psoriasis | Adbry |
| Eczema | Kyntheum |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In August, the company entered into an agreement to acquire Dersimelagon from Tanabe Pharma. |
| 2026 | Plans/Strategy | In March, the company announced its plans to raise the IPO of shares. |
| 2026 | Contracts/Agreements | In April, the company signed a definitive agreement to acquire Replay, a gene therapy company. |
Competitor Comparison
| Key Parameters | Leo Pharma AS | AbbVie Inc | Teva Pharmaceutical Industries Ltd | Bausch Health Companies Inc | UCB SA |
|---|---|---|---|---|---|
| Headquarters | Denmark | United States of America | Israel | Canada | Belgium |
| City | Ballerup | North Chicago | Tel Aviv | Laval | Anderlecht |
| State/Province | - | Illinois | Tel Aviv | Quebec | Bruxelles-Capitale |
| No. of Employees | 4,265 | 57,000 | 31,173 | 20,300 | 10,117 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jesper Brandgaard | Chairman | Executive Board | 2021 | - |
| Philip Eickhoff | Executive Vice President - Global Finance and Business Services; Chief Financial Officer | Senior Management | 2022 | - |
| Christophe Bourdon | Chief Executive Officer | Senior Management | - | 56 |
| Robert Spurr | Executive Vice President-North America | Senior Management | - | - |
| Jean Monin | Executive Vice President-Critical Care Business Unit | Senior Management | 2024 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer